Why AbbVie Wants Shire

Shares in Irish orphan and ADHD drug maker Shire Plc  shot up today on the news that AbbVie , faced with the oncoming patent loss for Humira and looking to lower its tax rate, made public a rejected $46.5 billion bid today. This was the third bid for Shire from AbbVie, and reportedly management is considering a fourth.

So, why does AbbVie want Shire? In the video below, health care analysts Michael Douglass and David Williamson discuss the proposed deal and what Shire has to offer AbbVie.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The article Why AbbVie Wants Shire originally appeared on Fool.com.

David Williamson owns shares of AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story